Cryo-Cell International, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended November 30, 2014. This is an annual filing; the provided text does not give a clear standalone fourth-quarter income statement or cash-flow comparison.
Business context
Cryo-Cell provides cellular processing and cryogenic storage, primarily for umbilical cord blood and cord tissue. Its U.S. operations are based in Oldsmar, Florida; the company and global affiliates report storing more than 300,000 specimens. Processing and storage fees are the main revenue source, supplemented by income from international licensees and royalties. The company operates as one reportable segment.
Key financial metrics
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $20.13 million | $18.99 million |
| Operating income | $1.98 million | $1.70 million |
| Net income | $554,000 | $27,000 |
| Basic and diluted EPS | $0.05 | $0.00 |
| Operating cash flow | $1.55 million | $822,000 |
| Cash and cash equivalents at year-end | $3.28 million | $3.93 million |
| Long-term debt | None reported | None reported |
- Processing and storage fees were $18.66 million, up about 5%; recurring annual storage-fee revenue increased 6%. Total revenue rose 6%.
- Cost of sales was $5.63 million, or 28% of revenue, the same proportion as in FY2013. Selling, general and administrative expense rose 8% to $12.25 million. Operating margin was approximately 9.8%, versus 9.0%.
- Net income improved substantially, but included approximately $794,000 of Mexico-related license income that management said would not recur. Interest expense was $1.15 million, primarily associated with revenue-sharing agreements (RSAs).
- Cash declined approximately $646,000. Operating cash flow was partly offset by $2.67 million spent on share repurchases. Investing cash flow included the release of approximately $764,000 from restricted escrow funds.
- Year-end current assets were $8.49 million and current liabilities were $9.13 million, a working-capital deficit of approximately $635,000. The company also reported a $2.30 million long-term RSA liability and a stockholders’ deficit of $10.73 million. Deferred revenue is a significant liability reflecting storage services to be provided in future periods.
Material changes and unusual items
- New cord-blood specimens processed fell 13% year over year, mainly due to lower volumes from international affiliates, particularly Ecuador. Higher average selling prices and growth in cord tissue service helped offset the decline.
- Licensee income rose to $1.47 million from $1.30 million, including the nonrecurring Mexico-related amount. India royalties contributed approximately $678,000.
- RSA payments increased to $1.93 million from $1.05 million. The RSA agreements have no definitive term; the company says it cannot currently estimate the projected cash flows needed to determine when to reduce the recorded liability. RSA payments are recorded as interest expense under its current approach.
- The company repurchased 1,088,296 shares during FY2014 for approximately $2.67 million. At year-end, it held 2,215,111 shares in treasury.
- The company wrote off approximately $26,000 of abandoned patents and trademarks in FY2014, compared with $379,000 in FY2013, as it curtailed certain menstrual stem-cell technology efforts. It had previously ceased offering a commercial menstrual stem-cell service due to limited market acceptance.
Outlook, risks and contingencies
- Management anticipated approximately $500,000 of discretionary capital expenditures over the next 12 months, principally for software and equipment. It expected cash, marketable securities and operating cash flow to fund known needs for at least 12 months, while noting that weaker revenue or higher expenses could require spending reductions or financing.
- The company cited competition, limited market penetration, reliance on international affiliates and their ability to pay, changing regulation, and dependence on a single collection-kit supplier as business risks. New cord-blood specimens and future storage revenue are important to growth.
- Management concluded that disclosure controls and internal control over financial reporting were not effective at year-end because of a material weakness in identifying and applying accounting for non-routine transactions and related documentation. Remediation work had begun but had not operated long enough to establish remediation. The auditor gave an unqualified opinion on the financial statements but did not audit or opine on internal control effectiveness.
- The filing reports that several legal matters were resolved or dismissed, including a shareholder derivative case dismissed in July 2014. Management said remaining ordinary-course matters were not expected to have a material adverse effect, while acknowledging litigation uncertainty.
- A shareholder-rights plan adopted in December 2014 generally treats a person reaching 20% ownership as an acquiring person, subject to exceptions and the plan’s terms. The rights were set to expire in December 2017 unless earlier changed or terminated.
Important facts for investors to verify
- Whether recurring storage revenue can offset the decline in new specimen processing and the loss of nonrecurring Mexico-related income.
- The collectability and aging of receivables: net receivables were $4.07 million, with a $1.98 million allowance for doubtful accounts; FY2014 bad-debt provision was $1.30 million.
- The economics and potential duration of the RSAs, including future cash payments and the $2.30 million recorded long-term liability.
- Progress in remediating the material weakness and the impact of any accounting corrections or control failures.
- Liquidity and capital allocation, including the working-capital deficit, planned capital expenditures, ongoing share repurchases, and the company’s stated 12-month cash sufficiency assumption.